Efficacy of constant long-term delivery of YM-58483 for the treatment of rheumatoid arthritis

Our findings suggest that continuous long-term application of appropriate CRAC inhibitors such as YM-58483 is a potential therapeutic strategy for global immunosuppression in RA.